Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
As larger organizations become more influential in the health care sector, the Code can help physicians navigate those organizations’ influence on their practices.
AMA J Ethics. 2020;22(3):E217-220. doi:
10.1001/amajethics.2020.217.
Upcoding and misrepresenting clinical information constitute fraud, cost a lot, and can result in patient harm and unnecessary procedures and prescriptions.
AMA J Ethics. 2020;22(3):E221-231. doi:
10.1001/amajethics.2020.221.
Corporatization in health care has complicated clinicians’ and organizations’ efforts to balance interests of individual patients against an organization’s bottom line.
AMA J Ethics. 2020;22(3):E187-192. doi:
10.1001/amajethics.2020.187.
Eleanor Fleming, PhD, DDS, MPH, Julie Frantsve-Hawley, PhD, and Myechia Minter-Jordan, MD, MBA
Continued separation of dental and oral health from general medical care generates unnecessary prescriptions and pain management that are neither restorative nor responsive to patients’ primary complaints.
AMA J Ethics. 2022;24(1):E48-56. doi:
10.1001/amajethics.2022.48.
Streamlining US health care business has raised unique privacy concerns. Bills and explanations of benefits contain protected health information that could be disclosed to someone other than the patient.
AMA J Ethics. 2016;18(3):279-287. doi:
10.1001/journalofethics.2016.18.3.pfor4-1603.